Lutrate 3 month Depot 22.5 mg powder and solvent for prolonged-release suspension for injection

Country: United Kingdom

Language: English

Source: myHealthbox

Active ingredient:

leuprorelin acetate

Available from:

mercury pharmaceuticals limited

ATC code:

L02AE02

INN (International Name):

leuprorelin acetate

Dosage:

22.5 mg

Pharmaceutical form:

Powder and solvent for prolonged-release suspension for injection.

Administration route:

via the intramuscular route

Units in package:

1 glass vial containing 22.5 mg

Prescription type:

POM - Prescription Only Medicine

Manufactured by:

gp-pharm s.a.

Therapeutic group:

Endocrine therapy. Hormones and related agents. Gonadotropin-releasing hormones analogues

Therapeutic indications:

Lutrate 3 month Depot is indicated for palliative treatment of hormone dependent advanced prostate cancer.

Authorization status:

Authorised

Authorization date:

2015-12-03

Patient Information leaflet

GP-Pharm:
Edición:
G. Maculart:
PR-LP3M604-UK-01
266P119-A
01
Material:
Tintas:
Tamaño:
ÓFSET BLANCO 50 G
1+1
Color:
NEGRO
180X 400 MM Hendido y Plegado:180 X 50 MM CON TREPADO
1/2
Producto: 
LUTRATE 3 MONTH DEPOT 22,5 MG UK
Fecha:
Edición:
14.10.15
Conforme:
CÓDIGOS
103513/LF/718/01
PR-LP3M604-UK-01
GP-Pharm:
Edición:
G. Maculart:
PR-LP3M604-UK-01
266P119-A
01
Material:
Tintas:
Tamaño:
ÓFSET BLANCO 50 G
1+1
Color:
NEGRO
180X 400 MM Hendido y Plegado:180 X 50 MM CON TREPADO
2/2
Producto: 
LUTRATE 3 MONTH DEPOT 22,5 MG UK
Fecha:
Edición:
14.10.15
Conforme:
CÓDIGOS

Summary of Product characteristics

/XWUDWHPRQWK'HSRWPJSRZGHUDQGVROYHQWIRUSURORQJHGUHOHDVH
VXVSHQVLRQIRULQMHFWLRQ
6XPPDU\RI3URGXFW&KDUDFWHULVWLFV8SGDWHG'HF_$PGLSKDUP0HUFXU\&RPSDQ\/LPLWHG
1DPHRIWKHPHGLFLQDOSURGXFW
/XWUDWHPRQWK'HSRWPJSRZGHUDQGVROYHQWIRUSURORQJHGUHOHDVHVXVSHQVLRQIRULQMHFWLRQ
4XDOLWDWLYHDQGTXDQWLWDWLYHFRPSRVLWLRQ
(DFKYLDOFRQWDLQVPJRIOHXSURUHOLQDFHWDWHHTXLYDOHQWWRPJOHXSURUHOLQIUHHEDVH
P/RIUHFRQVWLWXWHGVXVSHQVLRQFRQWDLQVPJRIOHXSURUHOLQDFHWDWH
_([FLSLHQWVZLWKNQRZQHIIHFW_
(DFKYLDOFRQWDLQVIURPWRPJPPRORIVRGLXPDVFDUPHOORVHVRGLXP
)RUWKHIXOOOLVWRIH[FLSLHQWVVHHVHFWLRQ
3KDUPDFHXWLFDOIRUP
3RZGHUDQGVROYHQWIRUSURORQJHGUHOHDVHVXVSHQVLRQIRULQMHFWLRQ
3RZGHUZKLWHWRRIIZKLWHSRZGHU
6ROYHQWFOHDUFRORUOHVVDQGSDUWLFOHIUHHVROXWLRQS+±
&OLQLFDOSDUWLFXODUV
7KHUDSHXWLFLQGLFDWLRQV
/XWUDWHPRQWK'HSRWLVLQGLFDWHGIRUSDOOLDWLYHWUHDWPHQWRIKRUPRQHGHSHQGHQWDGYDQFHGSURVWDWHFDQFHU
3RVRORJ\DQGPHWKRGRIDGPLQLVWUDWLRQ
3RVRORJ\
7KHXVXDOUHFRPPHQGHGGRVHRI/XWUDWHPRQWK'HSRWLVPJSUHVHQWHGDVDWKUHHPRQWKVGHSRWLQMHFWLRQDQG
DGPLQLVWHUHGDVDVLQJOHLQWUDPXVFXODULQMHFWLRQHYHU\WKUHHPRQWKV
/XWUDWHPRQWK'HSRWPXVWEHDGPLQLVWHUHGXQGHUGLUHFWLRQRIKHDOWKFDUHSURIHVVLRQDOKDYLQJWKHDSSURSULDWHH[SHUWLVH
IRUPRQLWRULQJWKHUHVSRQVHWRWUHDWPHQW
7KHGRVHRI/XWUDWHPRQWK'HSRWDOORZLQJWKHFRQWLQXRXVUHOHDVHRIOHXSURUHOLQDFHWDWHRYHUDWKUHHPRQWKSHULRGLV
LQFRUSRUDWHGLQDGHSRWIRUPXODWLRQ7KHO\RSKLOL]HGSRZGHUVKRXOGEHUHFRQVWLWXWHGDQGDGPLQLVWHUHGDVDVLQJOH
LQWUDPXVFXODULQMHFWLRQHYHU\WKUHHPRQWKV,QWUDDUWHULDORULQWUDYHQRXVDGPLQLVWUDWLRQPXVWEHDYRLGHG7KHYLDORI
/XWUDWHPRQWK'HSRWPLFURVSKHUHSRZGHUVKRXOGEHUHFRQVWLWXWHGLPPHGLDWHO\SULRUWRDGPLQLVWUDWLRQE\LQWUDPXVFXODU
LQMHFWLRQ$VZLWKRWKHUGUXJVDGPLQLVWHUHGUHJXODUO\E\LQMHFWLRQWKHLQMHFWLRQVLWHVKRXOGEHYDULHGSHULRGLFDOO\
/XWUDWHPRQWK'HSR